Caplacizumab is a von Willebrand factor (vWF)-directed antibody fragment designed to inhibit the interaction between vWF and platelets.

A recombinant form of human ADAMTS13 approved for a different condition helped to save the life of a young mother with immune thrombotic thrombocytopenic purpura. A team led by investigators from ...

Megakaryocytes, which are derived from hematopoietic stem cell precursors in bone marrow, form and release platelets; these circulate in the blood for 8 to 10 days before they are removed by hepatic ...

Every day, Sanofi employees work to chase the miracles of science and improve people’s lives by asking themselves “what if?” Our work is rooted in scientific curiosity centered on the question: What ...